Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy (HCM) is a frequent genetic cardiac disease and the most common cause of sudden cardiac death in young individuals. Most of the currently known HCM disease genes encode sarcomeric proteins. Previous studies have shown an association between CSRP3 missense mutations and either dilated cardiomyopathy (DCM) or HCM, but all these studies were unable to provide comprehensive genetic evidence for a causative role of CSRP3 mutations. We used linkage analysis and identified a CSRP3 missense mutation in a large German family affected by HCM. We confirmed CSRP3 as an HCM disease gene. Furthermore, CSRP3 missense mutations segregating with HCM were identified in four other families. We used a newly designed monoclonal antibody to show that muscle LIM protein (MLP), the protein encoded by CSRP3, is mainly a cytosolic component of cardiomyocytes and not tightly anchored to sarcomeric structures. Our functional data from both in vitro and in vivo analyses suggest that at least one of MLP's mutated forms seems to be destabilized in the heart of HCM patients harbouring a CSRP3 missense mutation. We also present evidence for mild skeletal muscle disease in affected persons. Our results support the view that HCM is not exclusively a sarcomeric disease and also suggest that impaired mechano-sensory stress signalling might be involved in the pathogenesis of HCM.

[1]  S. F. Konieczny,et al.  The muscle regulatory and structural protein MLP is a cytoskeletal binding partner of betaI-spectrin. , 2000, Journal of cell science.

[2]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[3]  D. Panagiotakos,et al.  Subclinical skeletal muscle abnormalities in patients with hypertrophic cardiomyopathy and their relation to clinical characteristics. , 2003, International journal of cardiology.

[4]  S. F. Konieczny,et al.  Muscle LIM protein promotes myogenesis by enhancing the activity of MyoD , 1997, Molecular and cellular biology.

[5]  Stefan Eulitz,et al.  Unusual splicing events result in distinct Xin isoforms that associate differentially with filamin c and Mena/VASP. , 2006, Experimental cell research.

[6]  H. Watkins,et al.  Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. , 2003, Trends in genetics : TIG.

[7]  R. Dietz,et al.  Mutations in the Human Muscle LIM Protein Gene in Families With Hypertrophic Cardiomyopathy , 2003, Circulation.

[8]  张哉根,et al.  Leu-M , 1991 .

[9]  A. Tajik,et al.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[10]  R. Lieber,et al.  Muscle LIM protein plays both structural and functional roles in skeletal muscle. , 2005, American journal of physiology. Cell physiology.

[11]  K. Osterziel,et al.  Decreased interactions of mutant muscle LIM protein (MLP) with N-RAP and α-actinin and their implication for hypertrophic cardiomyopathy , 2004, Cell and Tissue Research.

[12]  K. Lindenberg,et al.  Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. , 2005, Cardiovascular research.

[13]  H. Heng,et al.  Mapping of a human LIM protein (CLP) to human chromosome 11p15.1 by fluorescence in situ hybridization. , 1995, Genomics.

[14]  Daniel Auerbach,et al.  Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2 , 2002, Journal of Cell Science.

[15]  R. Körfer,et al.  Paxillin and ponsin interact in nascent costameres of muscle cells. , 2007, Journal of molecular biology.

[16]  Peter J. Nürnberg,et al.  HaploPainter: a tool for drawing pedigrees with complex haplotypes , 2005, Bioinform..

[17]  Michael J Ackerman,et al.  Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin. , 2006, Molecular genetics and metabolism.

[18]  W. Mckenna,et al.  Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. , 1997, Heart.

[19]  Masahiko Hoshijima,et al.  The Cardiac Mechanical Stretch Sensor Machinery Involves a Z Disc Complex that Is Defective in a Subset of Human Dilated Cardiomyopathy , 2002, Cell.

[20]  J E Edwards,et al.  Quantitative Analysis of Cardiac Muscle Cell Disorganization in the Ventricular Septum: Comparison of Fetuses and Infants with and Without Congenital Heart Disease and Patients with Hypertrophic Cardiomyopathy , 1979, Circulation.

[21]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[22]  K. Chien,et al.  Reversal of calcium cycling defects in advanced heart failure toward molecular therapy. , 2006, Journal of the American College of Cardiology.

[23]  M. Quiñones,et al.  Tissue Doppler Imaging Consistently Detects Myocardial Abnormalities in Patients With Hypertrophic Cardiomyopathy and Provides a Novel Means for an Early Diagnosis Before and Independently of Hypertrophy , 2001, Circulation.

[24]  Christine E. Seidman,et al.  α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere , 1994, Cell.

[25]  E. Fleck,et al.  Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[26]  M. Frenneaux,et al.  What is the mechanism of abnormal blood pressure response on exercise in hypertrophic cardiomyopathy? , 2003, Journal of the American College of Cardiology.

[27]  N. Smedira,et al.  Cytoskeletal structure and recovery in single human cardiac myocytes. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  P. Toutouzas,et al.  Electromyographic evidence of subclinical myopathy in hypertrophic cardiomyopathy , 2000, Muscle & nerve.

[29]  P. Caroni,et al.  Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation , 1994, Cell.

[30]  Christine E Seidman,et al.  The genetic basis for cardiac remodeling. , 2005, Annual review of genomics and human genetics.

[31]  L. Mestroni,et al.  Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. , 1999, European heart journal.

[32]  K. Siminovitch,et al.  W4R variant in CSRP3 encoding muscle LIM protein in a patient with hypertrophic cardiomyopathy. , 2005, Molecular genetics and metabolism.

[33]  B. Hainque,et al.  Familial hypertrophic cardiomyopathy: from mutations to functional defects. , 1998, Circulation research.

[34]  S. Lowey,et al.  Functional consequences of mutations in the myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy. , 2002, Trends in cardiovascular medicine.

[35]  J. Seidman,et al.  Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. , 2002, The Journal of clinical investigation.

[36]  H. Watkins,et al.  Altered Regulatory Properties of Human Cardiac Troponin I Mutants That Cause Hypertrophic Cardiomyopathy* , 2000, The Journal of Biological Chemistry.

[37]  P. Charron,et al.  The genetic bases of cardiomyopathies , 2006 .

[38]  K. Ohno,et al.  Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. , 2004, Brain : a journal of neurology.

[39]  Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults: Echocardiographic Analysis of 4111 Subjects in the Cardia Study , 1996 .

[40]  P. Caroni,et al.  Alterations at the Intercalated Disk Associated with the Absence of Muscle Lim Protein , 2001, The Journal of cell biology.

[41]  Minoru Hongo,et al.  MLP-Deficient Mice Exhibit a Disruption of Cardiac Cytoarchitectural Organization, Dilated Cardiomyopathy, and Heart Failure , 1997, Cell.

[42]  R. Schwartz,et al.  Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. , 2003, Molecular genetics and metabolism.

[43]  MichaelBöhm,et al.  Decreased Expression of the Cardiac LIM Domain Protein MLP in Chronic Human Heart Failure , 2000 .

[44]  M. Gautel,et al.  The structure of the sarcomeric M band: localization of defined domains of myomesin, M-protein, and the 250-kD carboxy-terminal region of titin by immunoelectron microscopy , 1996, The Journal of cell biology.

[45]  P. Caroni,et al.  Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure. , 2000, Circulation.

[46]  J. Seidman,et al.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy. , 2005, The New England journal of medicine.

[47]  H. Watkins Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies. , 2003, Circulation.

[48]  A. Yao,et al.  Effects of deletion of muscle LIM protein on myocyte function. , 2001, American journal of physiology. Heart and circulatory physiology.

[49]  H. A. Louis,et al.  Comparison of Three Members of the Cysteine-rich Protein Family Reveals Functional Conservation and Divergent Patterns of Gene Expression* , 1997, The Journal of Biological Chemistry.

[50]  J. Schmitt,et al.  The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. , 2002, The Journal of clinical investigation.

[51]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.